Pulmonx Insiders Sell 78,340 Shares

Several Pulmonx executives sold company shares on September 1, 2026, at $2.26 each. CEO Glendon French III sold 41,882 shares, General Counsel David Lehman sold 14,334, Chief Commercial Officer Geoffrey Rose Beran sold 7,879, and Chief Science and Technology Officer Radhakrishnan Srikanth sold 14,245, for a combined 68,340 shares worth about $154,448. The sales disclosed by the first three executives were described as covering tax-withholding obligations tied to vested equity awards, while the filings left the executives with substantial remaining holdings. Pulmonx recently reported a quarterly loss of 24 cents per share but exceeded analysts’ expectations, with revenue of $22.76 million versus a $22.39 million consensus estimate. Analysts’ ratings remain broadly favorable, with three Buy ratings and one Sell rating and an average price target of $7.67, well above the stock’s recent price near $2.21.